A randomized, open-label, multi-center study to evaluate the efficacy of nilotinib versus best supportive care with or without a tyrosine kinase inhibitor (investigator's choice) in adult patients with gastrointestinal stromal tumors resistant to both imatinib and sunitinib
Phase of Trial: Phase III
Latest Information Update: 19 Aug 2016
At a glance
- Drugs Nilotinib (Primary) ; Imatinib; Sunitinib
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms ENEST
- Sponsors Novartis
- 23 Jun 2012 Additional location (Belgium) added as reported by European Clinical Trials Database record.
- 12 Feb 2012 Results published in the Annals of Oncology.
- 04 Oct 2011 Actual end date of the extension trial (NCT00488150) is June 2011.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History